IDE modifications reg
This article was originally published in The Gray Sheet
Executive Summary
Publication of a final version of the rule could be held up until after the Nov. 21 deadline stipulated by the FDA Modernization Act because the Office of Management and Budget has determined that the rule is "significant" and worthy of OMB's review, FDAers say. OMB has 90 days from June 17 to review the rule before it can be issued as a proposed rule in the Federal Register. The rule, which will spell out which modifications may be made to an investigational device exemption product or protocol without FDA notification, is one of eight rules and guidances that the agency's device center had planned for release by September ("The Gray Sheet" June 29, p. 7)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.